

1 **Original Article**

2

3

4 **Proteomic profiles and cytokeratin 13 as a potential biomarker of Ovis aries Papillomavirus**  
5 **3-positive and negative cutaneous squamous cell carcinomas**

6

7

8 Veronica Vitiello<sup>a#</sup>, Giovanni P. Burrari<sup>a,b\*#</sup>, Salvatore Pisanu<sup>c</sup>, Carla Cacciotto<sup>a,b,c</sup>, Maria Filippa  
9 Addis<sup>b,c,d</sup>, Alberto Alberti<sup>a,b</sup>, Elisabetta Antuofermo<sup>a,b</sup>, Tiziana Cubeddu<sup>a,b</sup>, Salvatore Pirino<sup>a</sup>

10

11

12 <sup>a</sup> *Department of Veterinary Medicine, University of Sassari, Via Vienna 2, 07100, Sassari, Italy.*

13 <sup>b</sup> *Mediterranean Center for Disease Control, University of Sassari, Via Vienna 2, 07100, Sassari,*  
14 *Italy.*

15 <sup>c</sup> *Porto Conte Ricerche Srl, S.P. 55 Porto Conte/Capo Caccia Km 8.400, Tramariglio, 07041*  
16 *Alghero (SS), Italy.*

17 <sup>d</sup> *Department of Veterinary Medicine, University of Milan, Via Celoria 10, 20133, Milan, Italy.*

18

19

20

21

22

23 \*Corresponding Author: Telephone: +39079229440, *E-mail address:* gburrai@uniss.it (GP. Burrari)

24 #These authors contributed equally to this work

25 **Abstract**

26 *Ovis aries* papillomavirus 3 (OaPV3) is an epidermotropic PV reported in sheep cutaneous  
27 squamous cell carcinoma (SCC). The presence of OaPV3 DNA and its transcriptional activity in  
28 cutaneous SCC, as well as its *in vitro* transforming properties, suggest a viral etiology for this  
29 neoplasm. Nevertheless, the reactome associated with viral-host interaction is still unexplored.

30 Here, we investigated and compared the proteomic profiles of OaPV3-positive SCCs,  
31 OaPV3-negative SCCs, and non-SCC samples by liquid chromatography tandem-mass  
32 spectrometry (LC-MS/MS) analysis, bioinformatics tools, and immunohistochemistry (IHC).  
33 OaPV3-positive SCCs (n = 3), OaPV3-negative SCCs (n = 3), and non-SCCs samples (n = 3) were  
34 subjected to a shotgun proteomic analysis workflow to assess protein abundance differences among  
35 the three sample classes. Proteins involved in epithelial cell differentiation, extracellular matrix  
36 organization, and apoptotic signaling showed different abundances in OaPV3-positive SCCs tissues  
37 ( $P \leq 0.05$ ) when compared to the other tissues. Cytokeratin 13 (CK 13) was among the most  
38 increased proteins in OaPV3-positive SCC and was validated by immunohistochemistry on 10  
39 samples per class, confirming its potential as a biomarker of OaPV3 infection in SCC.

40 Collectively, results provide a preliminary insight into the reactome associated with viral-  
41 host interaction and pave the way to the development of specific biomarkers for viral-induced sheep  
42 SCC.

43

44 *Keywords:* Cytokeratin 13, papillomavirus, sheep, squamous cell carcinoma, reactome

45

46 **Introduction**

47 Squamous cell carcinoma (SCC) is a malignant tumor arising from the squamous epithelium  
48 of the skin and mucous membranes, widely reported in domestic animals and represents the most  
49 common form of skin tumor in sheep (Alberti et al., 2010; Tore et al., 2017; Vitiello et al., 2017;  
50 Goldschmidt et al., 2017).

51 Papillomavirus infection, along with several environmental risk factors, such as prolonged  
52 exposure to ultraviolet radiation of poorly pigmented skin, has been claimed to act as a major factor  
53 contributing to SCC development (Alberti et al., 2010; Ahmed et al., 2015). PVs are a large group  
54 of small, non-enveloped, double-stranded DNA viruses that infect skin and mucosae causing  
55 proliferative and neoplastic lesions in domestic and wild vertebrate species (Munday et al., 2010;  
56 Lange et al., 2011; Rector et al., 2013; Sardon et al., 2015; de Villiers et al., 2017; Lecis et al.,  
57 2020).

58 In sheep, four PV types, namely *Ovis aries* Papillomavirus 1 (OaPV1), 2 (OaPV2), 3  
59 (OaPV3), and 4 (OaPV4), have been fully sequenced and classified into two different genera  
60 (Alberti et al., 2010; Tore et al., 2017). OaPV1, OaPV2, and OaPV4 have been rescued from  
61 cutaneous fibropapillomas and belong to the *Delta* genus, while OaPV3 has been detected in  
62 cutaneous SCC and is the prototype of the *Dyokappa* genus (Alberti et al., 2010; Tore et al., 2017).  
63 Although the putative etiological role of *ovine PVs* both in cutaneous fibropapilloma and SCC has  
64 not yet been fully elucidated, it has been shown that OaPV3 expresses the typical E6/E7 oncogenes,  
65 and that OaPV3 E7 binds the retinoblastoma tumor suppressor protein (pRb) much more efficiently  
66 than fibropapilloma-related papillomaviruses, similarl to what has been observed in high and low -  
67 risk human PVs (Alberti et al., 2010; Tore et al., 2019). Additionally, the presence of both OaPV3  
68 DNA and transcripts in SCCs, as well as its in vitro transforming properties, point towards a  
69 contribution of OaPV3 to tumor development (Alberti et al., 2010; Vitiello et al., 2017; Tore et al.,  
70 2019).

71 Proteomic profiling technologies open the way to the discovery of novel biomarkers with  
72 potential as sensitive and specific molecular tools in cancer research (Mabert et al., 2014). The  
73 identification of altered proteins occurring in the oncogenesis process, as well as their qualitative  
74 and quantitative characterization, can offer valuable information relating to more effective  
75 diagnosis, prognosis, and response to therapy. Thus, the application of proteomics to ovine SCC  
76 appears particularly interesting in order to map the biological processes associated with viral  
77 infection, in which OaPV3 could play a pivotal role. Furthermore, characterizing the proteins  
78 involved in virus-host interactions can contribute to the identification of candidate biomarkers  
79 indicating viral activity. Based on these considerations, the aim of our study was to discover and  
80 validate OaPV3 infection-related proteins in ovine cutaneous SCC by proteomics and  
81 immunohistochemistry (IHC), in order to elucidate the pathways involved in viral neoplastic  
82 transformation and to identify potential viral biomarkers.

83

## 84 **Materials and Methods**

85

### 86 *Origin of the samples*

87 This study included a total of 30 archival tissue samples, of which 10 were OaPV3-positive SCCs,  
88 10 were OaPV3-negative SCCs, and 10 were non-SCC samples collected from the udder (n = 17)  
89 and the head (n = 13) of 30 Sarda breed sheep. All tissues belonged to a previous sampling study  
90 (Vitiello et al., 2017) in which specimens were divided in two aliquots, one of which was formalin-  
91 fixed, paraffin-embedded (FFPE), and used for histological evaluation and immunohistochemistry,  
92 while the other was frozen at -80°C for later proteomic analyses. In that study (Vitiello et al., 2017)  
93 the presence of OaPV3 in sheep SCC was assessed by conventional PCR, and its cellular  
94 localization and transcriptional activity were evaluated by ISH and RT-PCR. All SCCs were  
95 classified as moderately differentiated (except 1 classified as poorly differentiated) according to the

96 modified Anneroth's multifactorial histological grading system by two experienced (EA, SP) and  
97 one board-certified pathologist (GPB) (Vitiello et al., 2017).

98 Experiment permission was not required from the University's Animal Care Ethics  
99 Committee because all the samples were retrieved from the abattoir.

100

#### 101 *Protein extraction, in-gel digestion, shotgun analysis, and protein identification*

102 For proteomic analysis, frozen udder tissue samples from 3 moderately differentiated  
103 OaPV3-positive SCCs, 3 moderately differentiated OaPV3-negative SCCs, and 3 non-SCCs were  
104 selected among the 30 archival samples listed in the previous paragraph and characterized in our  
105 previous study (Vitiello et al., 2017). For protein extraction, the tissue replicates stored at -80°C  
106 were included in Optimal Cutting Temperature medium (Tissue-Tek, Sakura Finetek, Torrance,  
107 CA, USA), cut into 20 serial cryosections (Leica CM 1950, Heidelberg, Germany) at 10-µm, and  
108 collected in a 1.5-ml sterile tube. In parallel, serial cryostat sections (3-µm thick) from the same  
109 tissue were histologically evaluated in order to confirm their classification and to ensure that the  
110 lesions were present in the portion of the tissue subjected to proteomic analysis, as well as to re-  
111 assess non-SCC tissues. Total proteins were extracted from each tissue by incubating the respective  
112 10-µm cryosections in 200 µl of lysis buffer containing 2% sodium dodecyl sulphate (SDS), 0.4 %  
113 Tween-20, 130 mM dithiothreitol (DTT), 500 mM Tris HCl (pH 8.8) plus SIGMAFAST™ Protease  
114 Inhibitors (Sigma, St. Louis, MO, USA) at the concentration recommended by the manufacturers, at  
115 300 rpm for 15 min at 95 °C using a Thermomixer comfort (Eppendorf, Hamburg, Germany). After  
116 centrifugation at 10.000 x g for 10 min at 4° C, supernatants were quantified with the Pierce™ 660  
117 nm Protein Assay (Thermo Scientific). Protein extracts were processed to obtain peptide mixtures  
118 by means of the Filter Aided Sample Preparation (FASP) as previously described, starting from 100  
119 µg of protein extract (Wisniewski et al., 2009; Tanca et al., 2013). Then, liquid chromatography-  
120 tandem mass spectrometry (LC-MS/MS) analysis of tryptic digests was performed on a Q-TOF  
121 hybrid mass spectrometer with a nano lock Z spray source, coupled on-line with a NanoAcquity

122 chromatography system (Waters). Each peptide mixture was analyzed in duplicate and each sample  
123 was first concentrated, washed with an enrichment column, fractionated over a 250 min gradient on  
124 a C18 reverse-phase column and then analyzed by a data-dependent MS/MS mode as described  
125 previously (Ghisaura et al., 2019). Raw files were processed by ProteinLynx software (Version  
126 2.2.5) to produce the peak lists as pkl files. All pkl files were first converted into MGF files, and  
127 subsequently, Proteome Discoverer software (version 1.4; Thermo Scientific) was used for protein  
128 identification. Two technical replicates were analyzed as merge to generate a unique list of proteins  
129 for each biological sample using a workflow assembling by different nodes: Sequest-HT as a search  
130 engine (Protein Database: database homemade composed by concatenation of different databases  
131 obtained by UniProtKB; Taxonomy: *Bos taurus*, *Ovis aries* and *Capra hircus* sequences from  
132 SwissProt and Papillomaviridae sequences from TrEMBL; Enzyme: Trypsin; Maximum missed  
133 cleavage sites: 2; Precursor mass tolerance: 50 ppm; Fragment mass tolerance: 0.4 Da; Static  
134 modification: cysteine carbamidomethylation; Dynamic modification: N-terminal Glutamine  
135 conversion to Pyro-glutamic acid and methionine oxidation), and Percolator for peptide validation  
136 (peptide confidence: q-value < 0.01) (Kall et al., 2007; The et al., 2016). Peptide and protein  
137 grouping according to the Proteome Discoverer's algorithm were allowed, applying the strict  
138 maximum parsimony principle.

139

#### 140 *Label-free quantitation and data analysis*

141 Spectral counts (SpC) were used to estimate protein abundances and to compare the  
142 abundance of the same proteins between different sample groups (Addis et al., 2011; Pisanu et al.,  
143 2011; Tanca et al., 2013). The Normalized Spectral Abundance Factor (NSAF) of proteins was used  
144 to express their relative abundance and the SpC log Ratio (R<sub>sc</sub>) to express the log fold change of  
145 proteins between different experimental groups (Old et al., 2005; Zybailov et al., 2006). Proteins  
146 identified with less than one SpC in at least one replicate or with fewer than two SpCs in more than  
147 one replicate were excluded from the differential analysis, in order to increase the accuracy of the

148 analysis (Addis et al., 2011; Addis et al., 2013). Among proteins identified in the databases of *Bos*  
149 *taurus*, *Ovis aries*, and *Capra hircus* proteins, only those with the highest number of peptides and  
150 PSMs were considered.

151

#### 152 *Functional analysis of differential proteins*

153 All proteins showing statistically significant differences in OaPV3-positive SCCs, OaPV3-negative  
154 SCCs, and non-SCC tissues were subjected to pathway analysis based on the Gene Ontology (GO)  
155 database (biological processes (BP), molecular functions (MF), and cellular components (CC) ) and  
156 STRING (Szklarczyk et al., 2015; Pisanu et al., 2018). To enable pathway analysis, the UniProt  
157 codes for *Bos taurus*, *Ovis aries*, and *Capra hircus* were replaced with the UniProt codes for the  
158 closest human protein equivalent by sequence alignment of identified peptides with human  
159 sequences using Basic Local Alignment Search Tool (BLAST).

160

#### 161 *Immunohistochemistry*

162 Histological sections (3- $\mu$ m thick) of the 30 FFPE samples described in the first paragraph  
163 (OaPV3-positive SCCs, OaPV3-negative SCCs, non-SCC samples, 10 samples per class,  
164 respectively), were mounted on charged slides (Superfrost Ultra Plus, Thermo Scientific), as  
165 previously described (Banco et al., 2011). Briefly, slides were immersed for 20 min in a 98°C  
166 preheated solution (WCAP, BioOptica, Milan, Italy) and mounted in a sequenza chamber (Shandon,  
167 Runcorn, UK). Tissues were then blocked for endogenous peroxidase with a 1 h incubation in Dako  
168 REAL Peroxidase-Blocking Solution (S2023, Dako, Glostrup, Denmark), and for non-specific  
169 binding with a 1 h incubation in 2.5% normal horse serum (ImmPRESS reagent kit, Vector Labs,  
170 Burlingame, CA, USA). Subsequently, slides were incubated overnight at 4°C with rabbit  
171 polyclonal antibodies against CK 13 (ab58744, ABcam, Cambridge, UK) at 1:400. Next, slides  
172 were incubated for 30 min at room temperature with an anti-rabbit secondary antibody (ImmPRESS  
173 reagent kit, Vector Labs, Burlingame, CA, USA). After staining with 3,3'-Diaminobenzidine

174 (ImmPACT DAB, Vector Laboratories, Burlingame, CA, USA) tissues were counterstained with  
175 hematoxylin, cover-slipped with Eukitt Mounting Medium™ (BiOptica, Milan, Italy) and  
176 observed under light microscopy. Urinary bladder tissue sections were used as positive controls for  
177 CK 13. Negative controls were carried out by replacing the primary antibody with normal rabbit  
178 serum (Invitrogen, Milan, Italy).

179

#### 180 *Evaluation of immunohistochemical data*

181 The extent of CK 13 immunopositivity was evaluated by considering the cytoplasmic  
182 signals of the malignant squamous cells or non-neoplastic skin cells. Immunoreactivity was semi-  
183 quantitatively scored considering the number of positive cells in 10 HPF (grade 0: no positive cells;  
184 1: < 10%; 2: 11-30%; 3: 31-60%; 4: > 60%) and the intensity of staining (weak: 1; moderate: 2;  
185 strong: 3). Then, a combined immunoreactivity score (IRS) ranging from 1 to 12 was calculated for  
186 each specimen. Tissues were imaged using Nikon Eclipse 80i and digital computer images were  
187 recorded with a Nikon Ds-fi1 camera.

188

#### 189 *Statistical analysis*

190 All the statistical analyses, including descriptive statistics, were performed using Stata 11.2  
191 software (StataCorp LP), with statistical significance set as  $P \leq 0.05$ . To evaluate differentially  
192 abundant proteins (Rsc) among the experimental groups, we applied the beta-binomial test (Pham et  
193 al., 2010). Only proteins with  $Rsc \geq 1.5$  or  $\leq -1.5$  and with a P-value  $\leq 0.05$  obtained by the beta-  
194 binomial test were considered significant in the comparison between OaPV3-positive SCCs,  
195 OaPV3-negative SCCs, and non-SCC samples. To evaluate the differences between the principal  
196 biological processes obtained by STRING, we used NSAF values and Student t-test after checking  
197 the normality with the Shapiro-Wilk test. Abundances of the different biological processes were  
198 calculated by the sum of the NSAF values for each protein associated to a biological process (Addis  
199 et al., 2011).



200

## 201 **Results**

202

### 203 *Proteomic analysis of SCC and non-SCC sheep tissue samples*

204 A total of 476 proteins were successfully identified (Sheet 1 “1. All identified proteins”,  
205 Supplementary File). Of these, 242 were eligible for the differential analysis between OaPV3-  
206 positive SCCs, OaPV3-negative SCCs, and non-SCC tissues, by label-free quantitative proteomics.  
207 Differential proteomics results are reported in Table 1.

208

### 209 *Differential proteins between OaPV3-positive SCCs and OaPV3-negative SCCs*

210 A total of 28 proteins showed statistically significant differences ( $R_{sc} \geq 1.5$  and  $\leq -1.5$ ,  $P$ -  
211 value  $\leq 0.05$ ) when comparing OaPV3-positive with OaPV3-negative SCCs. Of these, 17 proteins  
212 were increased and 11 were decreased (Table 1, OaPV3 vs SCC, in bold; Sheet 2 “2. Pos SCCs vs  
213 Negative SCCs”, Supplementary File).

214

### 215 *Differential proteins between OaPV3-positive SCCs and non-SCC tissues*

216 A total of 43 proteins showed statistically significant differences ( $R_{sc} \geq 1.5$  and  $\leq -1.5$ ,  $P$ -  
217 value  $\leq 0.05$ ) when comparing OaPV3-positive SCCs with non-SCC tissues. Of these, 14 proteins  
218 were increased while 29 were decreased (Table 1, OaPV3 vs N, in bold; Sheet 3 “3. Pos SCCs vs  
219 non-SCC tissue”, Supplementary File).

220

### 221 *Differential proteins between OaPV3-negative SCCs and non-SCC tissues*

222 A total of 26 proteins showed statistically significant differences ( $R_{sc} \geq 1.5$  and  $\leq -1.5$ ,  $P$ -  
223 value  $\leq 0.05$ ) when comparing OaPV3-negative SCCs with non-SCC tissues. Of these, 7 proteins  
224 were increased and 19 were decreased (Table 1, SCC vs N, in bold; Sheet 4 “4. Neg SCCs vs non-  
225 SCC tissue”, Supplementary File).

226

227 *Biological and functional pathways involving differential proteins*

228 The proteins showing statistically significant changes belonged to numerous biological  
229 pathways related to the disease. The most relevant ones were response to stress (RS, 28 proteins),  
230 regulation of apoptotic signalling pathways (RASP, 7 proteins), negative regulation of apoptotic  
231 process and cell death (NRAP, 10 proteins), tissue development (TD, 18 proteins), epithelial cell  
232 differentiation (ECD, 8 proteins), extracellular matrix disassembly (EMD, 5 proteins) and  
233 organization (EMO, 9 proteins), and glycosaminoglycan catabolic process (GCP, 4 proteins).  
234 Differential proteins belonging to these pathways and significant in at least one sample group (bold  
235 type) are indicated in Table 1 with asterisks in each respective pathway column. Detailed  
236 information is reported in Supplementary File, Sheet 5 “5. Biological Process\_STRING” and sheet  
237 6 “6. Table with Gene Ontology”.

238 The biological pathways most represented in each SCC type and in non-SCC tissues were  
239 then assessed by considering the total abundance of all the proteins belonging to each pathway  
240 within the different sample groups (Fig.1). As a result, OaPV3-positive SCCs had a significantly  
241 higher abundance of proteins belonging to the functional classes RASP, NRAP, and NRCD when  
242 compared to both OaPV3-negative SCC and non-SCC tissues. OaPV3-positive SCCs also contained  
243 higher amounts of proteins belonging to the functional class RS when compared to non-SCC  
244 tissues. On the other hand, OaPV3-positive SCCs had lower amounts of proteins belonging to TD  
245 and ECD when compared to both OaPV3-negative SCC and non-SCC tissues. OaPV3-positive  
246 SCCs did also have lower amounts of proteins belonging to EMD and EMO when compared to  
247 non-SCC tissues. The proteins participating in each pathway are indicated in Table 1 with the  
248 respective abbreviations, and are detailed in the Supplementary file, Sheet 5 “Biological  
249 Process\_STRING”. Protein abundance values are detailed in Sheet 7 “7.NSAF”.

250 Reactome analysis was also carried out on all differential proteins to highlight common  
251 pathways involved in the development of SCC. The resulting protein network is reported in Fig. 2.

252 The most significantly represented pathway was “neutrophil degranulation”, followed by “innate  
253 immune system”. Of interest in the context of the disease was the significant involvement of  
254 “formation of the cornified envelope”, “degradation of the extracellular matrix”, as well as  
255 “Chk1/Chk2(Cds1) mediated inactivation of “Cyclin B:Cdk1 complex”. Results are detailed in  
256 Sheet 8 “8. Reactome\_STRING”, Supplementary file.

257

### 258 *Immunohistochemistry*

259 Among differentially expressed proteins, CK 13 was higher in OaPV3-positive SCCs when  
260 compared to either OaPV3-negative SCCs or non-SCC tissues, in both cases with high RSC values.  
261 To validate this observation, CK 13 abundance in the 3 sample classes was further investigated by  
262 IHC on a larger cohort (10 samples for each class) (Fig. 3). As a result, 10/10 OaPV3-positive  
263 SCCs (100%) showed diffuse and strong cytoplasmic CK 13 signals in the intermediate and  
264 superficial layers of malignant squamous cells, with rare signals in the epithelial basal layer.  
265 Specifically, 6/10 OaPV3-positive SCCs (60%) showed a strongly immunoreactive signal (IRS  
266 score = 12) (Fig. 3a), whereas 4/10 (40%) showed weak immunostaining (IRS score = 4) (Fig. 3b).  
267 Only 2 out of 10 OaPV3-negative SCCs (20%) showed a barely detectable signal in suprabasal cells  
268 (IRS score = 2), while no signal was detected in 8/10 OaPV3-negative SCC (80%, IRS score = 0)  
269 (Fig. 3c) and in 10/10 non-SCC samples (100%, IRS score = 0). Strong immunoreactivity was  
270 detected in the cytoplasm of the bladder epithelial cells used as positive controls, while no signal  
271 was observed in the negative controls.

272

### 273 **Discussion**

274 Proteomic analysis appears particularly interesting in cancer research, as both the study of  
275 tumor cell biology and the identification of altered cellular processes and of the specific proteins  
276 involved in these pathways represent key tools for investigating tumors (Srivastava et al., 2018).  
277 Investigating the reactome of diseased animals does also provide new insights in veterinary

278 medicine, helping to clarify molecular mechanisms dictating initiation and progression of different  
279 conditions, and allowing the identification of specific biomarkers that may be useful for establishing  
280 effective intervention and treatment control actions (Ceciliani et al., 2014; Lippolis et al., 2016).

281 Accordingly, when looking at the functional pathways involving the differential proteins  
282 identified in this study and at their reactome, a significantly higher abundance of proteins belonging  
283 to regulation of apoptotic signalling pathways, negative regulation of apoptotic process, and  
284 negative regulation of cell death, was found in OaPV3-positive SCC. These pathways are involved  
285 in SCC development and were related to the presence or absence of OaPV3 infection. On the other  
286 hand, other pathways associated with normal tissue and extracellular matrix organization were more  
287 abundant in non-SCC tissues, followed by OaPV3-negative SCC.

288 When investigating the reactome, the most significantly altered pathways in the investigated  
289 SCC tissues were related to neutrophil degranulation and the innate immune system as well as  
290 platelet degranulation and activation and, more in general, to the hemostasis system. It seems  
291 plausible that this might be related to the inflammatory reaction due to the high frequency of SCC  
292 ulceration, as observed in our cases, and frequently described also in goats (Gibbons et al., 2015).  
293 Furthermore, the role of tumor-associated neutrophils (TANs) has gained attention in cancer and  
294 has been linked to the overall survival of human patients with both oesophageal and head and neck  
295 squamous cell carcinoma (Shaul et al., 2019).

296 Concerning differential proteins, several were involved in SCC development and were  
297 related to the presence or absence of OaPV3 infection. Among proteins significantly higher in  
298 OaPV3-positive SCCs when compared to non-neoplastic samples, transgelin-2, annexin, pyruvate  
299 kinase, alpha-1-acid glycoprotein have been reported as key factors for the progression of human  
300 SCC (Croce et al., 2001; Calmon et al., 2013; Meng et al., 2017; Kurihara-Shimomura et al., 2018).  
301 Also, previous studies reported Annexin A1 overexpression in penile carcinomas positive for high-  
302 risk HPVs (Calmon et al., 2013).

303           Additionally, 14-3-3 proteins theta and zeta/delta (Table 1) were more abundant in SCCs  
304 harboring OaPv3 compared to non-neoplastic samples. The 14-3-3 proteins comprise a large family  
305 of highly conserved phosphoserine/threonine-binding proteins related to intracellular signaling,  
306 apoptosis signal transduction, and cell cycle regulatory pathways, and being also negative regulators  
307 of cell death and cellular senescence (van Hemert et al., 2001). Furthermore, their aberrations are  
308 involved in cellular transformation and tumorigenesis, due to their role as oncoproteins and tumor  
309 suppressor proteins regulators (Morrison, 2009; Pennington et al., 2018). Interestingly, similarly to  
310 what observed in OaPV3-positive SCC, 14-3-3 zeta protein increases in high-risk human  
311 papillomavirus (HPV)-related cervical cancer, providing further evidence of the relationship  
312 between PVs and this family of phosphoserine/threonine-binding proteins (Boon et al., 2013).  
313 Considering the specific interaction of the 14-3-3 zeta protein with the phosphorylated PDZ binding  
314 motif (PBM) of the E6 viral protein reported in cervical cancer, it seems plausible that the higher  
315 abundance of 14-3-3 proteins in OaPV3-positive SCCs might be exclusively related to the viral  
316 presence and that it may contribute to maintaining high levels of OaPV3 E6 protein (Boon et al.,  
317 2013). Future studies involving the dissection of the role of E6 and of its possible relation and  
318 effects on 14-3-3 activity, as well as the 14-3-3 downstream pathway including, for example, the  
319 AKT and P53 pathway, should provide fascinating insights into the function of the E6 OaPV3  
320 oncoprotein, considering also the unsolved p53 deregulation in ovine SCC cell proliferation (Tore et  
321 al., 2019).

322           Among the proteins decreased in OaPV3-positive SCCs when compared with the non-  
323 neoplastic tissue we found filaggrin 2, a protein involved in maintaining cell-cell adhesion and in  
324 the protection against UVB light, and transgelin-2, a protein that regulates actin cytoskeleton  
325 through actin binding and involved in cytoskeletal remodelling. Both proteins have been linked to  
326 human HPV-related cancer (Skaaby et al., 2014; Meng et al., 2017; Yang et al., 2019). Of interest is  
327 the observed overall decrease of galectins, including galectin-3, a  $\beta$  galactoside-binding protein,  
328 involved in tumor growth, progression, and metastasis, and considered a potential target to prevent

329 cancer metastasis (Ahmed et al., 2015). Similar to what observed in OaPV3-positive SCC, a  
330 decrease in galectin-3 was reported in human squamous and basal cell carcinomas (Kapucuoglu et  
331 al., 20019).

332         Among the 17 proteins significantly higher in OaPV3-positive SCCs when compared to  
333 OaPV3-negative SCCs, prosaposin, a lysosomal compartmental protein involved in catabolism of  
334 sphingolipids with small sugar chains, has been validated as oesophageal squamous cell carcinoma  
335 biomarker (Pawar et al., 2011).

336         Another interesting observation in the comparison of OaPV3-positive SCCs vs OaPV3-  
337 negative SCCs was the decreased abundance of proteins involved in epithelial cell differentiation  
338 and tissue development, such as type I and II cytokeratins (CKs), including CK 3, CK 6 and 15.  
339 This finding could be related to viral infection. Indeed, in our study, the markers for epidermal  
340 differentiation CK 3 and CK 6 were less abundant in OaPV3-positive SCC and more abundant in  
341 OaPV3-negative SCC, similarly to what reported in human cutaneous squamous cell carcinomas  
342 (Moll et al., 2008; Mommers et al., 2000). Nevertheless, *in vitro* studies have shown that the E1<sup>E4</sup>  
343 PV proteins are able to specifically bind CKs by a DEAD-box protein-mediated interaction,  
344 inducing the collapse of the cell cytoskeletal network (Raj et al., 2004). Likewise, our results  
345 support the deregulation of CK 6 induced by viral infection, and suggest an active role of OaPV3 in  
346 tissue development and epithelial cell differentiation.

347         Conversely, the increase in abundance of CK 13, a marker of epithelial differentiation for  
348 non-keratinizing epithelium such as the esophagus, appeared ambiguous considering also the  
349 observed decreased in the other proteins involved in epithelial cell differentiation and tissue  
350 development, as galectin-7 and transgelin-2 ( Lam et al., 1995). This finding appears of interest  
351 since no altered levels of CK 13 were observed in OaPV3-negative SCC and in non-neoplastic  
352 tissues compared to OaPV3-positive SCC samples, suggesting that the increased abundance of this  
353 protein might be tightly related to viral infection. Interestingly, Hudson and co-workers reported  
354 overexpression of this protein in human cutaneous SCC (Hudson et al., 2010). Our hypothesis is

355 further reinforced by the IHC results, with a strong (60% of cases) and diffuse expression of CK 13  
356 in OaPV3-positive malignant squamous cells, while no signal was detected in 100% of non-  
357 neoplastic tissue and in most (80%) of OaPV3-negative SCC.

358 Nevertheless, our data conflicted with previous reports showing the ability of HPV 16  
359 E1<sup>E4</sup> to bind CKs, inducing the collapse of the cell cytoskeletal network (Raj et al., 2004).  
360 Overall, it seems conceivable that the decrease in CK 6 and CK 3 may activate the well-known  
361 mechanism of cytokeratins compensation in which group I CK 13 is expressed in order to  
362 compensate the absence of group II CKs (CK 6 and 3) (Kanaji et al., 2007). In particular, type I and  
363 type II CKs have been shown to form obligate 1:1 heteropolymers, suggesting that dynamic  
364 changes must occur in their expression levels, particularly when one CK is suppressed.

365 A limitation of this study could be related to sampling size and storage conditions. In  
366 particular, a larger number of samples need to be systematically analyzed in order to make and  
367 further validate general assumptions. Moreover, storage conditions could have nuanced the  
368 proteomic features of virus-induced SCC. However, the storage condition used in this study  
369 (freezing at -80°C immediately after sampling) is commonly used in proteomics studies (Tanca et  
370 al., 2012). In addition, since both negative and positive samples underwent the same storage  
371 process, we hypothesize that the differential proteomic results are reliable and are significantly  
372 descriptive of the differences among OaPV3 positive, OaPV3 negative SCC, and non-SCC tissues.

373

## 374 **Conclusions**

375 To the best of our knowledge, this is the first study applying a comprehensive proteomic  
376 approach for investigating the deregulation of proteins related to viral infection in one of the most  
377 common ovine tumors, SCC. The altered biological processes as well as the SCC associated-  
378 reactome might be related to viral pathogenesis pathways, suggesting that OaPV3 can represent a  
379 driving force in neoplastic transformation, as proposed for several papillomavirus-related tumors.

380 The identification of altered molecular pathways involved in cell cycle and apoptosis,  
381 frequently reported in the literature as related to viral activity, envisages a specific virus-host  
382 interaction in which OaPV3 may favor malignant transformation. Considered together, our findings  
383 support a role of OaPV3 in the progression of cutaneous squamous cell carcinomas and recognized  
384 CK 13 as a promising putative biomarker of OaPV3 infection in ovine cutaneous SCCs, especially  
385 useful when the virus is undetectable in the tumor, and considering that OaPV3 specific antibodies  
386 suitable for IHC have not yet been developed.

387

### 388 **Declaration of conflicting interests**

389 The authors declared no potential conflicts of interest with respect to the research, authorship,  
390 and/or publication of this article.

391

### 392 **Acknowledgments**

393 The authors thank Dr. Marina Antonella Sanna for her support in the pathological specimen  
394 handling. This research was supported by the University of Sassari (Fondo di Ateneo per la Ricerca  
395 2019 - Far2019Pirino – Far2019Burrari)

396

### 397 **Appendix A: Supplementary material**

398 Supplementary data associated with this article can be found, in the online version, at doi:

399

### 400 **References**

401 Addis, M.F., Pisanu, S., Ghisaura, S., Pagnozzi, D., Marogna, G., Tanca, A., Biossa, G.,  
402 Cacciotto, C., Alberti, A., Pittau, M., et al., 2011. Proteomics and Pathway Analyses of the Milk  
403 Fat Globule in Sheep Naturally Infected by *Mycoplasma agalactiae* Provide Indications of the In  
404 Vivo Response of the Mammary Epithelium to Bacterial Infection. *Infection and Immunity* 79,  
405 3833-3845.

406

407 Addis, M.F., Pisanu, S., Marogna, G., Cubeddu, T., Pagnozzi, D., Cacciotto, C., Campesi, F.,  
408 Schianchi, G., Rocca, S., Uzzau, S., 2013. Production and release of antimicrobial and immune



409 defense proteins by mammary epithelial cells following *Streptococcus uberis* infection of sheep.  
410 *Infect Immun* 81, 3182-3197.  
411

412 Ahmed, A.F., Hassanein, K.M.A., 2012. Ovine and caprine cutaneous and ocular neoplasms.  
413 *Small Ruminant Res* 106, 189-200.  
414

415 Ahmed, H., AlSadek, D.M.M., 2015. Galectin-3 as a Potential Target to Prevent Cancer  
416 Metastasis. *Clin Med Insights-On* 9, 113-121.  
417

418 Alberti, A., Pirino, S., Pintore, F., Addis, M.F., Chessa, B., Cacciotto, C., Cubeddu, T., Anfossi,  
419 A., Benenati, G., Coradduzza, E., et al., 2010. *Ovis aries* Papillomavirus 3: A prototype of a  
420 novel genus in the family Papillomaviridae associated with ovine squamous cell carcinoma.  
421 *Virology* 407, 352-359.  
422

423 Banco, B., Antuofermo, E., Borzacchiello, G., Cossu-Rocca, P., Grieco, V., 2011. Canine  
424 ovarian tumors: an immunohistochemical study with HBME-1 antibody. *J Vet Diagn Invest* 23,  
425 977-981.  
426

427 Boon, S.S., Banks, L., 2013. High-Risk Human Papillomavirus E6 Oncoproteins Interact with  
428 14-3-3 zeta in a PDZ Binding Motif-Dependent Manner. *J Virol* 87, 1586-1595.  
429

430 Burrai, G.P., Tanca, A., De Miglio, M.R., Abbondio, M., Pisanu, S., Polinas, M., Pirino, S.,  
431 Mohammed, S.I., Uzzau, S., Addis, M.F., Antuofermo, E., 2015. Investigation of HER2  
432 expression in canine mammary tumors by antibody-based, transcriptomic and mass  
433 spectrometry analysis: is the dog a suitable animal model for human breast cancer? *Tumor Biol*  
434 36, 9083-9091.  
435

436 Calmon, M.F., Mota, M.T.D., Babeto, E., Candido, N.M., Girol, A.P., Mendiburu, C.F.,  
437 Bonilha, J.L., Silvestre, R.V.D., Rosa, B.M., Thome, J.A., et al., 2013. Overexpression of  
438 ANXA1 in Penile Carcinomas Positive for High-Risk HPVs. *Plos One* 8.  
439

440 Cecilian, F., Eckersall, D., Burchmore, R., Lecchi, C., 2014. Proteomics in Veterinary  
441 Medicine Applications and Trends in Disease Pathogenesis and Diagnostics. *Veterinary*  
442 *Pathology* 51, 351-362.  
443

444 Croce, M.V., Price, M.R., Segal-Eiras, A., 2001. Association of a alpha1 acidic glycoprotein  
445 and squamous cell carcinoma of the head and neck. *Pathol Oncol Res* 7, 111-117.  
446

447 Gil da Costa, R.M., Peleteiro, M.C., Pires, M.A., DiMaio, D., 2017. An Update on Canine,  
448 Feline and Bovine Papillomaviruses. *Transbound Emerg Dis* 64, 1371-1379.  
449

450 de Villiers, E.M., 2013. Cross-roads in the classification of papillomaviruses. *Virology* 445, 2-  
451 10.  
452

453 Fouad, Y.A., Aanei, C., 2017. Revisiting the hallmarks of cancer. *Am J Cancer Res* 7, 1016-  
454 1036.  
455

456 Fridman, J.S., Lowe, S.W., 2003. Control of apoptosis by p53. *Oncogene* 22, 9030-9040.  
457 Fuentes-Gonzalez, A.M., Contreras-Paredes, A., Manzo-Merino, J., Lizano, M., 2013. The  
458 modulation of apoptosis by oncogenic viruses. *Virol J* 10, 182.  
459

460 Ghisaura, S., Pagnozzi, D., Melis, R., Biosa, G., Slawski, H., Uzzau, S., Anedda, R., Addis,  
461 M.F., 2019. Liver proteomics of gilthead sea bream (*Sparus aurata*) exposed to cold stress. *J*  
462 *Therm Biol* 82, 234-241.

463

464 Gibbons, P.M., Lamb, L., Mansell, J., 2015. Presentation, treatment, and outcome of squamous  
465 cell carcinoma in the perineal region of 9 goats. *Can Vet J* 56, 1043-1047.

466

467 Goldschmidt, M.H., Goldschmidt, K.H., 2017. Epithelial and Melanocytic Tumors of the Skin.  
468 In: Meuten DJ, ed. *Tumors in domestic animals*, 5th edition. Wiley Blackwell, USA.

469

470 Hudson, L.G., Gale, J.M., Padilla, R.S., Pickett, G., Alexander, B.E., Wang, J., Kusewitt, D.F.,  
471 2010. Microarray analysis of cutaneous squamous cell carcinomas reveals enhanced expression  
472 of epidermal differentiation complex genes. *Mol Carcinog* 49, 619-629.

473

474 Kall, L., Canterbury, J.D., Weston, J., Noble, W.S., MacCoss, M.J., 2007. Semi-supervised  
475 learning for peptide identification from shotgun proteomics datasets. *Nat Methods* 4, 923-925.

476

477 Kanaji, N., Bandoh, S., Fujita, J., Ishii, T., Ishida, T., Kubo, A., 2007. Compensation of type I  
478 and type II cytokeratin pools in lung cancer. *Lung Cancer-J Iaslc* 55, 295-302.

479

480 Kapucuoglu, N., Basak, P.Y., Bircan, S., Sert, S., Akkaya, V.B., 2009. Immunohistochemical  
481 galectin-3 expression in non-melanoma skin cancers. *Pathol Res Pract* 205, 97-103.

482

483 Kurihara-Shimomura, M., Sasahira, T., Nakashima, C., Kuniyasu, H., Shimomura, H., Kirita,  
484 T., 2018. The Multifarious Functions of Pyruvate Kinase M2 in Oral Cancer Cells. *Int J Mol Sci*  
485 19.

486

487 Lam, K.Y., Loke, S.L., Shen, X.C., Ma, L.T., 1995. Cytokeratin expression in non-neoplastic  
488 oesophageal epithelium and squamous cell carcinoma of the oesophagus. *Virchows Arch* 426,  
489 345-349.

490

491 Lange, C.E., Favrot, C., 2011. Canine papillomaviruses. *Vet Clin North Am Small Anim Pract*  
492 41, 1183-1195.

493

494 Lippolis, R., De Angelis, M., 2016. Proteomics and human diseases. *J Proteomics Bioinform* 9:  
495 063-074.

496

497 Lecis, R., Mucedda, M., Pidinchedda, E., Zobba, R., Pittau, M., Alberti, A., 2020. Genomic  
498 characterization of a novel bat-associated Circovirus detected in European *Miniopterus*  
499 *schreibersii* bats. *Virus Genes* 56, 325-328.

500

501 Mabert, K., Cojoc, M., Peitzsch, C., Kurth, I., Souchelnytskyi, S., Dubrovskaya, A., 2014. Cancer  
502 biomarker discovery: Current status and future perspectives. *Int J Radiat Biol* 90, 659-677.

503

504 Meng, T., Liu, L.C., Hao, R.F., Chen, S.Y., Dong, Y.L., 2017. Transgelin-2: A potential  
505 oncogenic factor. *Tumor Biol* 39.

506

507 Moll, R., Divo, M., Langbein, L., 2008. The human keratins: biology and pathology. *Histochem*  
508 *Cell Biol* 129, 705-733.

509

510 Mommers, J.M., van Rossum, M.M., van Erp, P.E.J., van de Kerkhof, P.C.M., 2000. Changes in  
511 keratin 6 and keratin 10 (co-)expression in lesional and symptomless skin of spreading  
512 psoriasis. *Dermatology* 201, 15-20.  
513

514 Morrison, D.K., 2009. The 14-3-3 proteins: integrators of diverse signaling cues that impact cell  
515 fate and cancer development. *Trends Cell Biol* 19, 16-23.  
516

517 Munday, J.S., Kiupel, M., 2010. Papillomavirus-Associated Cutaneous Neoplasia in Mammals.  
518 *Veterinary Pathology* 47, 254-264.  
519

520 Munday, J.S., 2014. Bovine and Human Papillomaviruses: A Comparative Review. *Veterinary*  
521 *Pathology* 51, 1063-1075.  
522

523 Old, W.M., Meyer-Arendt, K., Aveline-Wolf, L., Pierce, K.G., Mendoza, A., Sevinsky, J.R.,  
524 Resing, K.A., Ahn, N.G., 2005. Comparison of label-free methods for quantifying human  
525 proteins by shotgun proteomics. *Mol Cell Proteomics* 4, 1487-1502.  
526

527 Pawar, H., Kashyap, M.K., Sahasrabudhe, N.A., Renuse, S., Harsha, H.C., Kumar, P., Sharma,  
528 J., Kandasamy, K., Marimuthu, A., Nair, B., et al., 2011. Quantitative tissue proteomics of  
529 esophageal squamous cell carcinoma for novel biomarker discovery. *Cancer Biol Ther* 12, 510-  
530 522.  
531

532 Pennington, K.L., Chan, T.Y., Torres, M.P., Andersen, J.L., 2018. The dynamic and stress-  
533 adaptive signaling hub of 14-3-3: emerging mechanisms of regulation and context-dependent  
534 protein-protein interactions. *Oncogene* 37, 5587-5604.  
535

536 Pham, T.V., Piersma, S.R., Warmoes, M., Jimenez, C.R., 2010. On the beta-binomial model for  
537 analysis of spectral count data in label-free tandem mass spectrometry-based proteomics.  
538 *Bioinformatics* 26, 363-369.  
539

539 Pisanu, S., Cubeddu, T., Cacciotto, C., Pilicchi, Y., Pagnozzi, D., Uzzau, S., Rocca, S., Addis,  
540 M.F., 2018. Characterization of paucibacillary ileal lesions in sheep with subclinical active  
541 infection by *Mycobacterium avium* subsp paratuberculosis. *Vet Res* 49.  
542

543 Pisanu, S., Ghisaura, S., Pagnozzi, D., Biosa, G., Tanca, A., Roggio, T., Uzzau, S., Addis, M.F.,  
544 2011. The sheep milk fat globule membrane proteome. *J Proteomics* 74, 350-358.  
545

546 Raj, K., Berguerand, S., Southern, S., Doorbar, J., Beard, P., 2004. E1 empty set E4 protein of  
547 human papillomavirus type 16 associates with mitochondria. *J Virol* 78, 7199-7207.  
548

549 Rector, A., Van Ranst, M., 2013. Animal papillomaviruses. *Virology* 445, 213-223.  
550

551 Sardon, D., Blundell, R., Burrai, G.P., Alberti, A., Tore, G., Passino, E.S., Antuofermo, E.,  
552 2015. Absence of canine papillomavirus sequences in canine mammary tumours. *J Comp Pathol*  
553 152, 172-176.  
554

555 Scheffner, M., Werness, B.A., Huibregtse, J.M., Levine, A.J., Howley, P.M., 1990. The E6  
556 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of  
557 p53. *Cell* 63, 1129-1136.  
558

559 Shaul, M.E., Fridlender, Z.G., 2019. Tumour-associated neutrophils in patients with cancer. *Nat*  
560 *Rev Clin Oncol* 16, 601-620.

561  
562 Skaaby, T., Husemoen, L.L., Jorgensen, T., Johansen, J.D., Menne, T., Szecsi, P.B., Stender, S.,  
563 Bager, P., Thyssen, J.P., Linneberg, A., 2014. Associations of filaggrin gene loss-of-function  
564 variants and human papillomavirus-related cancer and pre-cancer in Danish adults. *Plos One* 9,  
565 e99437.  
566  
567 Srivastava, A., Creek, D.J., 2019. Discovery and Validation of Clinical Biomarkers of Cancer:  
568 A Review Combining Metabolomics and Proteomics. *Proteomics* 19, e1700448.  
569  
570 Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J.,  
571 Simonovic, M., Roth, A., Santos, A., Tsafou, K.P., et al., 2015. STRING v10: protein-protein  
572 interaction networks, integrated over the tree of life. *Nucleic Acids Res* 43, D447-452.  
573  
574 Tanca, A., Pagnozzi, D., Burrari, G.P., Polinas, M., Uzzau, S., Antuofermo, E., Addis, M.F.,  
575 2012. Comparability of differential proteomics data generated from paired archival fresh-frozen  
576 and formalin-fixed samples by GeLC-MS/MS and spectral counting. *J Proteomics* 77, 561-576.  
577  
578 Tanca, A., Pisanu, S., Biossa, G., Pagnozzi, D., Antuofermo, E., Burrari, G.P., Canzonieri, V.,  
579 Cossu-Rocca, P., De Re, V., Eccher, A., et al., 2013. Application of 2D-DIGE to formalin-fixed  
580 diseased tissue samples from hospital repositories: results from four case studies. *Proteomics*  
581 *Clin Appl* 7, 252-263.  
582  
583 The, M., MacCoss, M.J., Noble, W.S., Kall, L., 2016. Fast and Accurate Protein False  
584 Discovery Rates on Large-Scale Proteomics Data Sets with Percolator 3.0. *J Am Soc Mass*  
585 *Spectrom* 27, 1719-1727.  
586  
587 Tore, G., Cacciotto, C., Anfossi, A.G., Dore, G.M., Antuofermo, E., Scagliarini, A., Burrari,  
588 G.P., Pau, S., Zedda, M.T., Masala, G., et al., 2017. Host cell tropism, genome characterization,  
589 and evolutionary features of OaPV4, a novel Deltapapillomavirus identified in sheep  
590 fibropapilloma. *Vet Microbiol* 204, 151-158.  
591  
592 Tore, G., Dore, G.M., Cacciotto, C., Accardi, R., Anfossi, A.G., Bogliolo, L., Pittau, M., Pirino,  
593 S., Cubeddu, T., Tommasino, M., et al., 2019. Transforming properties of ovine  
594 papillomaviruses E6 and E7 oncogenes. *Vet Microbiol* 230, 14-22.  
595  
596 van Hemert, M.J., Steensma, H.Y., van Heusden, G.P., 2001. 14-3-3 proteins: key regulators of  
597 cell division, signalling and apoptosis. *Bioessays* 23, 936-946.  
598  
599 Vitiello, V., Burrari, G.P., Agus, M., Anfossi, A.G., Alberti, A., Antuofermo, E., Rocca, S.,  
600 Cubeddu, T., Pirino, S., 2017. *Ovis aries* Papillomavirus 3 in Ovine Cutaneous Squamous Cell  
601 Carcinoma. *Vet Pathol* 54, 775-782.  
602  
603 Wisniewski, J.R., Zougman, A., Nagaraj, N., Mann, M., 2009. Universal sample preparation  
604 method for proteome analysis. *Nat Methods* 6, 359-362.  
605  
606 Yang, R., Klimentova, J., Gockel-Krzikalla, E., Ly, R., Gmelin, N., Hotz-Wagenblatt, A.,  
607 Rehulkova, H., Stulik, J., Rosl, F., Niebler, M., 2019. Combined Transcriptome and Proteome  
608 Analysis of Immortalized Human Keratinocytes Expressing Human Papillomavirus 16 (HPV16)  
609 Oncogenes Reveals Novel Key Factors and Networks in HPV-Induced Carcinogenesis.  
610 *mSphere* 4.  
611

612 Zybailov, B., Mosley, A.L., Sardu, M.E., Coleman, M.K., Florens, L., Washburn, M.P., 2006.  
613 Statistical analysis of membrane proteome expression changes in *Saccharomyces cerevisiae*. *J*  
614 *Proteome Res* 5, 2339-2347.

615 **Table 1**


616 Differential proteins and their biological function in OaPV3-positive SCC vs OaPV3-negative SCC (OaPV3 vs SCC), OaPV3-positive SCC vs non-  
617 SCC (OaPV3 vs N), and OaPV3-negative SCC vs non-SCC (SCC vs N), respectively. Values are expressed in relative spectral counts ( $R_{SC}$ ).  
618 Differences in abundance are reported as fold changes in the respective sample comparisons. Statistically significant differential values are in bold:  
619  $R_{sc} \leq -1.5$  or  $\geq 1.5$ , beta-binomial test  $P \leq 0.05$ . Protein identities obtained upon BLAST search. Response to stress (RS), regulation of apoptotic  
620 signaling pathway (RASP), negative regulation of apoptotic process (NRAP), negative regulation of cell death (NRCD), tissue development (TD),  
621 epithelial cell differentiation (ECD), extracellular matrix disassembly (EMD), extracellular matrix organization (EMO), glycosaminoglycan  
622 catabolic process (GCP)

Accession	Gene Name	Protein name	OaPV3 vs SCC	OaPV3 vs N	SCC vs N	Biological process								
						RS	RASP	NRAP	NRCD	TD	ECD	EMD	EMO	GCP
Q99877	HIST1H2BN	Histone H2B type 1-N	<b>3.37</b>	1.48	<b>-1.91</b>									
P13796	LCP1	Plastin-2	<b>3.33</b>	0.42	<b>-2.94</b>							*	*	
P13646	KRT13	Keratin, type I cytoskeletal 13	<b>3.20</b>	<b>2.54</b>	-	*								
P69905	HBA1	I alpha globin	<b>2.64</b>	<b>1.57</b>	-1.09									
P07602	PSAP	Prosaposin	<b>2.61</b>	1.10	-	*			*	*	*			
Q8IVF2	AHNAK2	Protein AHNAK2	<b>2.47</b>	<b>1.81</b>	-									
P22309	UGT1A1	UDP-glucuronosyltransferase 1-1	<b>2.47</b>	1.46	-	*								
O75594	PGLYRP1	Peptidoglycan recognition protein 1	<b>2.40</b>	-0.25	-	*								*
Q04917	YWHAH	14-3-3 protein theta	<b>2.38</b>	<b>3.36</b>	-		*							
O14950	MYL12B	Myosin regulatory light chain 12B	<b>2.26</b>	<b>2.47</b>	-0.89									
P08238	HSP90AB1	Heat shock protein HSP 90-beta	<b>1.95</b>	1.28	-				*	*				*
P00558	PGK1	Phosphoglycerate kinase	<b>1.95</b>	-0.24	<b>-2.21</b>					*	*			
P36871	PGM1	Phosphoglucomutase-1	<b>1.80</b>	1.48	-									

Q09666	AHNAK	Neuroblast differentiation-associated protein AHNAK	<b>1.75</b>	1.16	-0.62															
P29034	S100A2	Protein S100-A2	<b>1.69</b>	1.40	-															
P49913	CAMP	Cathelicidin antimicrobial peptide	<b>1.59</b>	-0.72	-0.31	*														*
P68871	HBB	Hemoglobin subunit beta	<b>1.53</b>	<b>1.57</b>	0.01	*														
P37802	TAGLN2	Transgelin-2	1.40	<b>1.68</b>	0.26							*	*							
P09211	GSTP1	Glutathione S-transferase P	1.36	<b>2.18</b>	0.80	*	*	*	*											
P14618	PKM	Pyruvate kinase	1.31	<b>2.62</b>	1.29							*								
B9A064	IGLL5	Immunoglobulin lambda-like polypeptide 5	1.29	<b>1.83</b>	0.51	*														
P50454	SERPINH1	Serpin H1	1.09	<b>1.78</b>	0.67	*						*								*
P14174	MIF	Macrophage migration inhibitory factor	0.95	-0.75	<b>-1.73</b>	*	*	*	*											
P08758	ANXA5	Annexin	0.84	<b>2.41</b>	<b>1.55</b>	*		*	*											
P63104	YWHAZ	14-3-3 protein zeta/delta	0.75	<b>1.93</b>	1.16	*	*	*	*											
P00441	SOD1	Superoxide dismutase [Cu-Zn]	0.69	-0.83	<b>-1.54</b>	*	*	*	*	*	*									
P10909	CLU	Clusterin	0.69	-2.05	<b>-2.76</b>	*	*	*	*											
P68371	TUBB4B	Tubulin beta-4B chain	0.59	3.15	<b>2.53</b>	*														
P02763	ORM1	Alpha-1-acid glycoprotein	0.14	<b>1.95</b>	<b>1.78</b>	*														
P09493	TPM1	Tropomyosin alpha-1 chain	0.07	<b>-1.62</b>	<b>-1.72</b>	*														*
P01861	IGHG4	Ig gamma-4 chain C region	-0.02	1.82	<b>1.81</b>															
P07585	DCN	Decorin	-0.34	<b>-1.64</b>	-1.32	*						*		*	*	*	*	*	*	*
P12111	COL6A3	Collagen alpha-3(VI) chain	-0.46	<b>-1.71</b>	-1.27														*	*
P68104	EEF1A1	Elongation factor 1-alpha 1	-0.48	1.22	<b>1.68</b>															
P35754	GLRX	Glutaredoxin-1	-0.78	<b>-2.12</b>	-1.36							*								
P18206	VCL	Vinculin	-0.83	<b>-1.96</b>	-1.15	*														
P12109	COL6A1	Collagen alpha-1(VI) chain	-0.96	<b>-2.45</b>	-1.51							*		*	*					
P02765	AHSG	Alpha-2-HS-glycoprotein	-0.97	<b>-1.90</b>	-0.96	*													*	
P07951	TPM2	Tropomyosin beta chain	-1.06	<b>-2.35</b>	-1.32															
Q9BXN1	ASPN	Asporin	-1.31	<b>-2.67</b>	-1.38							*								
P20774	OGN	Mimecan	<b>-1.55</b>	<b>-3.43</b>	<b>-1.90</b>															*
P01834	IGKC	Ig kappa chain C region	<b>-1.70</b>	0.00	0.74															
P04264	KRT1	Keratin, type II cytoskeletal 1	<b>-1.86</b>	<b>-2.47</b>	-0.63	*						*								
P51888	PRELP	Prolargin	-1.92	<b>-2.55</b>	-0.65															*

P47929	LGALS7	Galectin-7	<b>-2.00</b>	<b>-2.36</b>	-0.38			
A2N2W8	VL6	VL6 protein	<b>-2.00</b>	0.00	0.77			
P04264	KRT1	Keratin, type II cytoskeletal 1	<b>-2.27</b>	<b>-2.86</b>	-0.61	*		*
Q01995	TAGLN	Transgelin	<b>-2.34</b>	<b>-3.05</b>	-0.73			* *
P62736	ACTA2	Actin, aortic smooth muscle	<b>-3.67</b>	<b>-4.15</b>	-0.51			* *
P19012	KRT15	Keratin, type I cytoskeletal 15	<b>-4.77</b>	0.00	2.77	*		*
P12035	KRT3	Keratin, type II cytoskeletal 3	<b>-4.88</b>	0.00	<b>2.61</b>			* *
P48668	KRT6C	Keratin, type II cytoskeletal 6C	<b>-5.89</b>	0.00	<b>5.27</b>			






623

624 Fig. 1. Comparative abundance of biological processes related to the differential proteins observed  
 625 when comparing OaPV3-positive SCCs (red), OaPV3-negative SCCs (violet) and non-SCC samples  
 626 (green). Data are shown as mean  $\pm$  s.d. from n=3 samples. †  $P \leq 0.05$ , *t*-test comparing OaPV3-  
 627 positive SCCs to non-SCC samples. ‡  $P \leq 0.05$ , *t*-test comparing OaPV3-positive SCCs to OaPV3-  
 628 negative SCCs.

629

630




631

632 Fig. 2. Reactome network according to STRING. Proteins associated with Innate Immune System,  
 633 Formation of the cornified envelope, Collagen biosynthesis and modifying enzymes, Degradation of  
 634 the extracellular matrix, and Extracellular matrix organization are indicated in purple, red, green,  
 635 yellow and pink, respectively. Seven different colored lines link nodes and represent seven types of  
 636 evidence used in predicting associations. Green lines: neighborhood evidence; red lines: presence of  
 637 fusion evidence; blue lines: co-occurrence evidence; black lines: co-expression evidence; purple  
 638 lines: experimental evidence; light blue lines: database evidence; yellow lines: text-mining  
 639 evidence.

640

641



642

643 Fig. 3. Immunohistochemistry of cytokeratin 13. Strong (3a) immunoreactivity detected in the  
644 intermediate (thin arrow) and superficial layers (thick arrow) of OaPV3-positive malignant  
645 squamous cells. Weak (3b) immunosignal observed in intermediate layers (thin arrow) of OaPV3-  
646 positive malignant squamous cells. No immunostain (3c) was detected in OaPV3-negative  
647 squamous cell carcinoma. Bar 10  $\mu$ m.